A COVID-19 vaccine being developed by the University of Oxford and British pharmaceutical company AstraZeneca was found to have an average efficacy rate of 70 percent following a large-scale trial.
The trial involved two separate dosing regimens, one which showed a 90 percent efficacy rate, and the other with 62 percent.
Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said the results “show that we have an effective vaccine that will save many lives.”
The Oxford vaccine is said to be cheaper, requires simpler storage and is easier to transport than those developed by Pfizer and Moderna.
